Retatrutide inyowani synthetic peptide yakagadzirwa kuti panguva imwe chete ishandise matatu akakosha receptors anobatanidzwa muglucose homeostasis uye simba chiyero: glucagon receptor (GCGR), glucose-inotsamira insulinotropic polypeptide receptor (GIPR) uye glucagon-yakafanana peptide-1 receptor (GLP- 1R) (Finan et al., 2023, The New England Journal of Medicine).Nekunongedza aya mareceptor, retatrutide inotevedzera mhedzisiro yeavo endogenous ligands, glucagon, GIP uye GLP-1, ari mahormone anodzora glucose metabolism uye uremu hwemuviri mumatishu akasiyana, senge pancreas, chiropa, uropi, adipose tishu uye gastrointestinal. turakiti (Drucker, 2023, Nature).
Kusiyana neiyo endogenous ligands, ine pfupi hafu yehupenyu, nekukurumidza kushatisa nedipeptidyl peptidase-4 (DPP-4) enzyme uye zvisingadiwi mhedzisiro, senge hypoglycemia uye kusvotwa (Drucker, 2023, Nature), retatrutide yakagadzirwa kuti ikunde izvi. miganhu.Retatrutide ndeye fusion peptide inoumbwa neyakagadziridzwa glucagon kutevedzana kwakabatana kune yakagadziridzwa GLP-1 kutevedzana kuburikidza neGIP sequence (Finan et al., 2023, The New England Journal of Medicine).Iko kugadziridzwa kunosanganisira amino acid kutsiva uye kudzima kunowedzera kugadzikana, potency uye kusarudzwa kwepeptide kune matatu receptors (Finan et al., 2023, The New England Journal of Medicine).
Retatrutide yakaratidza zvinoshamisa zvemishonga yemishonga uye kurapa kwakanaka mukufutisa uye Type 2 chirwere cheshuga mune preclinical uye kiriniki zvidzidzo.Mumhando dzemhuka dzekufutisa uye chirwere cheshuga, retatrutide yakaratidza mhedzisiro yepamusoro pakudzikisa mazinga eglucose eropa, kukurudzira insulin secretion, kudzvanya glucagon secretion, kunonoka kubuda kwegastric, kuderedza kudya kwekudya uye uremu hwemuviri zvichienzaniswa neamwechete kana maviri agonist evatatu vanogamuchira (Gault et. al., 2023, Chirwere cheshuga, Kufutisa uye Metabolism; Coskun et al., 2023a, Molecular Metabolism).Retatrutide yakavandudzawo lipid profile, kushanda kwechiropa, kuzvimba uye moyo nemoyo paramita mumhuka idzi (Gault et al., 2023, Diabetes, Obesity uye Metabolism; Coskun et al., 2023a, Molecular Metabolism).
Mumiyedzo yekiriniki yevanhu, retatrutide yakaratidzawo mhedzisiro inovimbisa muvarwere vakafuta uye vane chirwere cheshuga.Retatrutide yakatenderwa zvakanaka uye yakaratidza mhedzisiro-inotsamira pakudzikisa mazinga eglucose eropa, kukurudzira insulin secretion, kudzvanya glucagon secretion uye kuderedza kudya muchikamu chekutanga chidzidzo chinosanganisira vanozvipira vane hutano uye varwere vane Type 2 chirwere cheshuga (Coskun et al., 2023b, Diabetes Care) )Retatrutide yakawana kusvika ku17.5% inoreva kuderedza uremu pamasvondo makumi maviri nemana kana ichienzaniswa ne placebo muchikamu chechipiri chekudzidza chinosanganisira varwere vane kufutisa uye kuwandisa.Uku kurasikirwa kwehuremu kwaiperekedzwa nekuvandudzwa kweglycemic control, lipid profile, kushanda kwechiropa uye hupenyu hwehupenyu (Lilly's phase 2 retatrutide zvabuda zvakaburitswa muThe New England Journal of Medicine inoratidza mamorekuru ekuferefeta akasvika kusvika 17.5% zvinoreva kuderedza uremu pamavhiki makumi maviri nemana vakuru vane kufutisa uye kuwandisa., 2023).Retatrutide zvakare yaive neyakanaka chengetedzo mbiri isina yakakomba zviitiko kana hypoglycemia episodes yakataurwa.
Mufananidzo 1. Retatrutide (LY3437943) inhibisa glycated hemoglobin A1c (HbA1c) kukosha (A) uye bodyweight (B) nekufamba kwenguva.
(Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, novel katatu GIP, GLP-1, uye glucagon receptor agonist muvanhu vane Type 2 chirwere cheshuga: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet.
Retatrutide parizvino iri kuvandudzwa naEli Lilly neKambani semumiriri mutsva wezvinodhaka wekufutisa uye Type 2 chirwere cheshuga.Iyo inomiririra nzira itsva yekunongedza akawanda ma receptors anobatanidzwa muglucose metabolism uye simba rekuenzanisa nemorekuru rimwe chete.Retatrutide yakaratidza kushanda kunoshamisa mumhando dzemhuka uye kuyedzwa kwevanhu nekuchengetedza kwakanaka uye kushivirira profiles.Zvimwe zvidzidzo zvinodikanwa kusimbisa mabhenefiti ayo enguva refu uye njodzi dzinogona kuitika muhuwandu hwakakura uye hwakasiyana.Retatrutide inogona kupa sarudzo nyowani kune varwere vari kunetseka nekufutisa uye chirwere cheshuga uye vanoda mamwe marapirwo anoshanda.
Isu tiri mugadziri wepolypeptide muChina, tine makore akati wandei ehunyanzvi mukugadzira polypeptide.Hangzhou Taijia Biotech Co, Ltd inyanzvi yepolypeptide mbishi kugadzira, iyo inogona kupa makumi ezviuru zvepolypeptide mbishi zvinhu uye inogona zvakare kugadzirwa zvinoenderana nezvinodiwa.Hunhu hwezvigadzirwa zvepolypeptide hwakanakisa, uye kuchena kunogona kusvika 98%, iyo yave ichizivikanwa nevashandisi pasi rese.Welcome to consult us.
